Uterine Artery Occlusion for Fibroid Related Bleeding

Inclusion Criteria:

• 25 to 50 years of age

• Subject has a negative urine or blood pregnancy test prior to the procedure. At thetime of enrollment to the study, the subject has no intent of further childbearing andintends to use appropriate contraception throughout the first 12 months of the studyperiod (unless sterilized)

• Normal pap smear within 36 months of study procedure (most recent)

• Cervix suitable for tenaculum placement as determined by pelvic exam (adequate lengthof cervix, absence of cervical fibroid/lower fibroid to prevent clamp placement)

• At least one intra-mural or sub-serosal or sub-mucosal uterine fibroid with a minimumdiameter of greater than or equal to 3 cm, and all fibroids with a diameter less thanor equal to 8cm with a prevailing pathology (e.g., as opposed to adenomyosis) offibroids determined through ultrasound

• Symptomatic subject presenting with at least one of the following fibroid symptoms:pelvic pressure, menorrhagia, metrorrhagia, pelvic pain, increasing abdominal girth ordyspareunia due to fibroids.

• Subject has evidence of bilateral ureteric flow

• Subject agrees to participate in the study, including completion of all study-relatedprocedures and evaluations, and documents this agreement by signing the EthicsCommittee-approved informed consent.

Exclusion Criteria:

• Pregnancy as confirmed by positive urine or blood pregnancy test

• Menopausal as defined by elevated follicle-stimulating hormone (FSH) and decreasedoestradiol hormone levels as determined by the hospital local laboratory referencerange criteria

• Presence of any pedunculated sub-mucosal or pedunculated sub-serosal fibroid(s) asdetermined by MRI, ultrasound or hysteroscopy

• Presence of an intra-uterine device (IUD)

• Any hydronephrosis as determined on renal ultrasound prior to the procedure

• Clinical history of any thrombo-embolic disease or known thrombophilia

• Blood Urine Nitrogen (BUN) greater than 7.2mmol/L* and/or serum creatinine greaterthan 106μmol/L* unresolved with change in diet or hydration

• History or current evidence of gynecologic malignancy (confirmed by hysteroscopy orendometrial biopsy), atypical endometrial hyperplasia, or chronic pelvic inflammatorydisease

• Pelvic mass outside the uterus other than uterine fibroids

• Any current acute or chronic systemic infection or localized pelvic infection,including a urinary tract infection

• Use of Gonadotropin-Releasing Hormone (GnRH) agonist, danozol or mifepristone within 6-months prior to the start of the study procedure

• Using anticoagulation therapy (except over the counter treatments (e.g. aspirin)), orhave an underlying bleeding disorder

• Unsuitable for MRI examination (e.g. severe claustrophobia, non-MRI-compatibleimplanted metalloid devices)

• Prior endometrial ablation, uterine artery embolization, or uterine artery ligation

• Poor procedural candidate due to medical conditions as determined by the investigator (e.g. anesthesia class, renal insufficiency, heart disease);